Literature DB >> 15064839

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.

Jun-Hong Deng1, Liu-Ping Yang, Liang-Sheng Wang, De-Fan Zhou.   

Abstract

AIM: To evaluate the effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients.
METHODS: Forty-nine prostate cancer patients with their BMD determined were divided into two groups: the non-treated group included 21 patients before the commencement of ADT and the treated group, 28 patients, who had received ADT for more than 1 year. BMD was measured by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck.
RESULTS: Thirteen (62 %) non-treated and 23 (82 %) treated patients fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for age-matched control in lumbar spine and femoral neck were -0.9 +/- 0.7 and -0.6 +/- 0.5, respectively, in the treated group, and -1.8 +/- 1.1 and -1.6 +/- 1.0, respectively, in the non-treated group, the differences between the two groups were highly significant (P<0.01).
CONCLUSION: Prostate cancer patients who received ADT for more than 1 year had a significantly lower BMD in the lumbar spine and femoral neck than those before the beginning of ADT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064839

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  6 in total

Review 1.  Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

Review 2.  Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2015-01-31       Impact factor: 3.633

3.  Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Authors:  C-T Wu; Y-H Yang; P-C Chen; M-F Chen; W-C Chen
Journal:  Osteoporos Int       Date:  2015-05-20       Impact factor: 4.507

4.  Risk stratification in the hormonal treatment of patients with prostate cancer.

Authors:  Matthew A Uhlman; Judd W Moul; Ping Tang; Danielle A Stackhouse; Leon Sun
Journal:  Ther Adv Med Oncol       Date:  2009-09       Impact factor: 8.168

5.  The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.

Authors:  Pouran Famili; Jane A Cauley; Susan L Greenspan
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

6.  Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study.

Authors:  Sung Han Kim; Jae Young Joung; Sohee Kim; Koon Ho Rha; Hyeong Gon Kim; Cheol Kwak; Ji Youl Lee; Seong Soo Jeon; Sung Kyu Hong; Hyeon Jeong; Moon Ki Jo; Dalsan You; In Gab Jeong; Jun Hyuk Hong; Choung-Soo Kim
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.